Drug Trial Radar · NCT01421511
TR-701 FA vs Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections
Last checked: Nov 20, 2026Latest source record: Aug 29, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
666
Actual
Start
Sep 15, 2011
Primary completion
Jan 10, 2013
Study completion Jan 10, 2013
Sponsor
- Lead sponsor
- Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)Industry
- Sponsor type
- Industry
- First posted
- Aug 22, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, double-blind, double-dummy, multicenter, global Phase 3 study of IV to oral TR-701 FA 200 mg once daily for 6 days versus IV to oral Zyvox® (linezolid) 600 mg every 12 hours for 10 days for the treatment of ABSSSI in adults. Patients are to start treatment with at least 2 IV doses and may receive IV therapy for the entire treatment duration. Approximately 100 to 140 sites globally will participate in this study. Patients with an ABSSSI caused by suspected or documented gram positive pathogen(s) at baseline will be randomized 1:1 to study treatment.
Conditions
- Skin and Subcutaneous Tissue Bacterial Infections
Interventions
TR-701 FADrug
* TR-701 FA 200 mg once daily in 250 mL sterile saline for injection as a 60 minute IV infusion * TR-701 FA Tablets, 200 mg, orally once daily
LinezolidDrug
* Linezolid 600 mg IV Injection twice daily in 300 mL sterile saline for injection as a 60 minute IV infusion * Linezolid Tablets, 600 mg, orally every 12 hours
Primary outcomes
What the sponsor says the trial is designed to measure.
- The Early Clinical Response RateTime frame: 48-72 hours
Locations
117 sites in 11 countries. Site status is shown where the registry gives one.
Trius investigator site 159
Dothan, Alabama
Trius investigator site 103
Chula Vista, California
Trius investigator site 143
Escondido, California
Trius investigator site 105
La Mesa, California
Trius investigator site 106
Long Beach, California
Trius investigator site 157
Long Beach, California
Trius investigator site 142
National City, California
Trius investigator site 170
San Diego, California
Trius investigator site 167
Santa Ana, California
Trius investigator site 168
Stockton, California
Trius investigator site 141
Sylmar, California
Trius investigator site 139
Denver, Colorado
Trius investigator site 137
Newark, Delaware
Trius investigator site 166
Edgewater, Florida
Trius investigator site 101
Columbus, Georgia
Trius investigator site 138
Carmel, Indiana
Trius investigator site 144
Owensboro, Kentucky
Trius investigator site 150
Baton Rouge, Louisiana
Trius investigator site 165
Eunice, Louisiana
Trius investigator site 154
Boston, Massachusetts
Trius investigator site 146
Springfield, Massachusetts
Trius investigator site 136
West Roxbury, Massachusetts
Trius investigator site 163
Royal Oak, Michigan
Trius investigator site 153
Minneapolis, Minnesota
Trius investigator site 149
Picayune, Mississippi
Trius investigator site 164
Creve Coeur, Missouri
Trius investigator site 160
Las Vegas, Nevada
Trius investigator site 147
Teaneck, New Jersey
Trius investigator site 140
Columbus, Ohio
Trius investigator site 162
Lima, Ohio
Trius investigator site 161
Rapid City, South Dakota
Trius investigator site 155
Franklin, Tennessee
Trius investigator site 145
Memphis, Tennessee
Trius investigator site 169
Smyrna, Tennessee
Trius investigator site 148
Houston, Texas
Trius investigator site 354
Buenos Aires, Argentina
Trius investigator site 355
Buenos Aires, Argentina
Trius investigator site 351
Cludad Autonoma de Buenos Aires, Argentina
Trius investigator site 358
La Plata, Argentina
Trius investigator site 357
Mar del Plata, Argentina
Showing 40 of 117 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.